Acceleration of Cerebral Noradrenaline Turnover After Morphine Withdrawal and Its Retardation by Acute Morphine Administration in Rats
Overview
Authors
Affiliations
To clarify the effects of withdrawal from chronic morphine treatment on cerebral noradrenaline (NA) turnover, we have measured the alpha-methyl-p-tyrosine (alpha MT)-induced depletion of NA in five brain areas of male Wistar rats given morphine twice daily for 40 or 60 days. After the last morphine dose (50 or 70 mg/kg) the rats were withdrawn for 1, 2 or 4 days. In order to study the development of tolerance a challenge dose of 10 mg/kg of morphine was given to some of the rats. Withdrawal of morphine accelerated the alpha MT-induced NA depletion clearly in the hemispheres and the lower brain stem and slightly in the diencephalon. The acceleration was more pronounced in the brains of rats treated for 60 days than of those treated for 40 days. In the hemispheres the acceleration of NA depletion occurred at 1 and 2 days, in the diencephalon at 2 days, and in the lower brain stem at 2 and 4 days after morphine withdrawal. The most pronounced acceleration of NA depletion coincided with the maximum withdrawal-induced weight loss. The challenge dose of morphine clearly retarded the alpha MT-induced NA depletion in the hemispheres of control rats treated chronically with saline. This retardation was even more pronounced in rats withdrawn from chronic morphine treatment for 1 or 2 days. The challenge dose slightly accelerated the alpha MT-induced NA depletion in the lower brain stem of control rats.(ABSTRACT TRUNCATED AT 250 WORDS)
Opioid Intoxication to Withdrawal: A Case of Takotsubo Cardiomyopathy.
Zaidi K, Chapagain P, Mahmud A Cureus. 2024; 16(5):e59484.
PMID: 38826989 PMC: 11142866. DOI: 10.7759/cureus.59484.
Zharkovsky A, Totterman A, Moisio J, Ahtee L Naunyn Schmiedebergs Arch Pharmacol. 1993; 347(5):483-6.
PMID: 8321324 DOI: 10.1007/BF00166739.
Fernandez-Lopez A, Soria C, Revilla V, Gomez T, Calvo P Neurochem Res. 1994; 19(4):445-9.
PMID: 7915011 DOI: 10.1007/BF00967322.
Cuellar B, de Alba J, Leza J, Lorenzo P Psychopharmacology (Berl). 1995; 118(3):347-53.
PMID: 7617828 DOI: 10.1007/BF02245965.
Attila L, Ahtee L Naunyn Schmiedebergs Arch Pharmacol. 1984; 327(3):201-7.
PMID: 6541759 DOI: 10.1007/BF00502450.